myosin inhibitor – Talk Bio

Actionable Insights Powered by AI

Braveheart Bio Launches with $185 Million Series A, Appoints Biogen CEO Christopher Viehbacher as Chair

1 month ago talkbio0Tagged Andreessen Horowitz, BHB-1893, Biogen CEO, Braveheart Bio, Christopher Viehbacher, Forbion, Hypertrophic Cardiomyopathy, myosin inhibitor, OrbiMed, Series A financing

Braveheart Bio; Series A financing; hypertrophic cardiomyopathy; Christopher Viehbacher; Biogen CEO; cardiovascular drug development; BHB-1893; myosin inhibitor; Andreessen Horowitz; Forbion; OrbiMed

Bayer Secures Exclusive Rights to Aficamten in Japan Through Licensing Agreement with Cytokinetics

1 year ago talkbio0Tagged Aficamten, Bayer, Cytokinetics, Heart, Hypertrophic Cardiomyopathy, Japan, licensing agreement, myosin inhibitor

Bayer, Cytokinetics, Aficamten, Japan, Licensing Agreement, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor